To the Editor, Recently in Familial Cancer, Hermel et al. reported that multi-gene panel testing for hereditary cancer susceptibility "changed cancer screening and management guidelines from that expected based on family history alone in 13.2% of patients" [1] . Patients often seek testing for reassurance that family members carry no predisposing genes. Could the patients who tested negative be offered that reassurance? Were management recommendations changed for those patients?
Multi-gene panel testing has allowed the identification of germline deleterious mutations responsible for more than 90% of the familial breast cancer syndromes and is now offered patients who are either young at diagnosis, have a strong family history, or both. However, current guidelines recommend that once a patient tests negative (and another affected family member also tests negative) future screening and prophylactic treatments should still be based on the personal and family history, just as it was years ago before we had multi-gene panel testing to offer patients [2] .
The basis for this apparent paradox is that the elimination by multi-gene panel testing for the common cancer predisposing genes has not been shown to appreciably change the risk of a germline mutation (as yet not part of the panel) having been inherited by a particular patient. That likelihood remains related to the personal and family history (i.e. whether the patient meets the clinical criteria
